$4246 | SAVE $749 | Single User
$8492 | SAVE $1,498 | Site License
$12737 | SAVE $2,248 | Enterprise License

Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024

Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024
[Lowest Price Guaranteed: $4,246]

Published by Global Data: 03 Nov 2015 | 27212 | In Stock
Related Topics: Dermatitis , Drug

Introduction

Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024

Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData’s 2014 to 2024 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.

The US dominates the global atopic dermatitis market by value and volume, with an estimated market size of .1 billion and a diagnosed prevalent population of 5.8 million in 2014, of which 3.7 million patients were drug-treated.

With guidelines recommending topical corticosteroids for the majority of patients and moisturizers or emollients at first line of therapy, these drug classes contributed 66.64% to the 2014 sales value. However, these classes represent the crowded, saturated, generic portion of the US atopic dermatitis market, with little room for innovative products.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in US.

Table of Contents
for Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 5

    1.2 List of Figures 7

    2 Introduction 8

    2.1 Catalyst 8

    2.2 Related Reports 8

    2.3 Upcoming Related Reports 9

    3 Disease Overview 10

    3.1 Etiology and Pathophysiology 10

    3.1.1 Etiology 10

    3.1.2 Pathophysiology 11

    3.2 Symptoms 15

    4 Disease Management 17

    4.1 Diagnosis and Treatment Overview 17

    4.1.1 Diagnosis 17

    4.1.2 Treatment Guidelines 19

    4.1.3 Leading Prescribed Drugs for the Treatment of Atopic Dermatitis 21

    4.1.4 Clinical Practice 23

    4.2 US 24

    5 Competitive Assessment 30

    5.1 Overview 30

    5.2 Strategic Competitor Assessment 31

    5.3 Product Profiles - Major Brands 32

    5.3.1 Protopic (tacrolimus) 32

    5.3.2 Elidel 40

    5.3.3 Cyclosporine (numerous generic names) 45

    5.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 50

    5.4 Product Profiles - Off-Label Therapies 52

    5.4.1 Xolair (omalizumab) 52

    5.4.2 Actimmune (interferon gamma-1b) 57

    6 Opportunity and Unmet Need 62

    6.1 Overview 62

    6.1.1 A Systemic Drug for Severe Recalcitrant Patients 63

    6.1.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 66

    6.1.3 A Drug that Effectively Controls Patients’ Pruritus 70

    6.1.4 Further Research into the Pathophysiology of Atopic Dermatitis 72

    6.1.5 A Drug that Induces Disease Remission 75

    6.1.6 Improved Quality of Life for Both Patients and their Carers 76

    7 Pipeline Assessment 79

    7.1 Overview 79

    7.2 Clinical Trial Mapping 80

    7.2.1 Clinical Trials by Therapy Type 80

    7.3 Promising Drugs in Clinical Development 81

    7.3.1 Dupilumab (SAR231893/ REGN668) 84

    7.3.2 AN2728 97

    7.3.3 Other Drugs in Development 109

    8 Market Outlook 111

    8.1 US 111

    8.1.1 Forecast 111

    8.1.2 Key Events 115

    8.1.3 Drivers and Barriers 115

    9 Appendix 118

    9.1 Bibliography 118

    9.2 Abbreviations 131

    9.3 Methodology 133

    9.4 Forecasting Methodology 133

    9.4.1 Diagnosed Atopic Dermatitis Patients 133

    9.4.2 Percent Drug-treated Patients 134

    9.4.3 Drugs Included in Each Therapeutic Class 134

    9.4.4 Launch and Patent Expiry Dates 134

    9.4.5 General Pricing Assumptions 135

    9.4.6 Individual Drug Assumptions 136

    9.4.7 Generic Erosion 138

    9.4.8 Pricing of Pipeline Agents 138

    9.5 Physicians and Specialists Included in this Study 139

    9.6 Primary Research - Prescriber Survey 141

    9.7 About the Authors 142

    9.7.1 Author 142

    9.7.2 Reviewer 142

    9.7.3 Epidemiologist 143

    9.7.4 Global Director of Therapy Analysis and Epidemiology 143

    9.7.5 Global Head of Healthcare 144

    9.8 About GlobalData 145

    9.9 Disclaimer 145

List Of Tables
in Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024

1.1 List of Tables

Table 1: Symptoms of Atopic Dermatitis 16

Table 2: Treatment Guidelines for Atopic Dermatitis 21

Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2014 23

Table 4: Country Profile - US 28

Table 5: Leading Treatments for Atopic Dermatitis, 2014 32

Table 6: Product Profile - Protopic 34

Table 7: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 35

Table 8: Protopic SWOT Analysis, 2015 38

Table 9: Global Sales Forecasts ($m) for Protopic, 2014-2024 40

Table 10: Product Profile - Elidel 41

Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 42

Table 12: Elidel SWOT Analysis, 2015 44

Table 13: Global Sales Forecasts ($m) for Elidel, 2014-2024 45

Table 14: Product Profile - Cyclosporine 47

Table 15: Cyclosporine SWOT Analysis, 2015 49

Table 16: Global Sales Forecasts ($m) for Cyclosporine, 2014-2024 50

Table 17: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2015 51

Table 18: Product Profile - Xolair 53

Table 19: Xolair SWOT Analysis, 2015 55

Table 20: Global Sales Forecasts ($m) Xolair, 2014-2024 56

Table 21: Product Profile - Actimmune 58

Table 22: Actimmune SWOT Analysis, 2015 60

Table 23: Global Sales Forecasts ($m) Actimmune, 2014-2024 61

Table 24: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 63

Table 25: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2015 66

Table 26: Late-Stage Atopic Dermatitis Pipeline, 2015 83

Table 27: Product Profile - Dupilumab 86

Table 28: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of December 2014 89

Table 29: Dupilumab SWOT Analysis, 2015 95

Table 30: Global Sales Forecasts ($m) for Dupilumab, 2014-2024 96

Table 31: Product Profile - AN2728 99

Table 32: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29) 100

Table 33: AN2728 SWOT Analysis, 2015 106

Table 34: Global Sales Forecasts ($m) for AN2728, 2014-2024 108

Table 35: Drugs in Early-stage Clinical Development for Atopic Dermatitis, 2015 109

Table 36: Sales Forecasts ($m) for Atopic Dermatitis in the US, 2014-2024 113

Table 37: Key Events Impacting Sales for Atopic Dermatitis in the US, 2014-2024 115

Table 38: Drivers and barriers of the atopic dermatitis market in the US during the forecast period. 115

Table 39: Key Launch Dates 134

Table 40: Key Patent Expiries 134

Table 41: Physicians Surveyed, By Country 141

List Of Figures, Charts and Diagrams
in Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024

1.2 List of Figures

Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin 13

Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis 20

Figure 3: Atopic Dermatitis Therapeutics - Clinical Trials by Therapy Type and Development Stage, October 2015 81

Figure 4: Atopic Dermatitis - Phase III Pipeline, December 2014 82

Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2014-2024 83

Figure 6: Sales for Atopic Dermatitis in the US by Drug Class, 2014-2024 114

Additional Details

Publisher

Global Data

Publisher Information

Reference

27212 | GDHC301CFR

Number of Pages

146

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies
Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness...
15 Nov 2018 by GBI Research USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - Pipeline Review, H1 2017
Atopic Dermatitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and...
15 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $9,346 (normally
USD $10,995)
More Info
SAVE 15% today! Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade has ...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade h...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade has...
03 Nov 2015 by Global Data USD $5,946 (normally
USD $6,995)
More Info
SAVE 15% today! Atopic Dermatitis - Current and Future Players
Atopic Dermatitis - Current and Future PlayersSummaryGlobalData has released its pharma report, “Ato...
03 Nov 2015 by Global Data USD $2,546 (normally
USD $2,995)
More Info
SAVE 15% today! Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade h...
03 Nov 2015 by Global Data USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024SummaryAlthough the past decade has...
03 Nov 2015 by Global Data USD $5,946 (normally
USD $6,995)
More Info
SAVE 15% today! Atopic Dermatitis - Current and Future Players
Atopic Dermatitis - Current and Future PlayersSummaryGlobalData has released its pharma report, “Ato...
03 Nov 2015 by Global Data USD $2,546 (normally
USD $2,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...